The bronchodilating responses to 400 pg salbutamol and 80 ug ipratropium bromide were studied in 188 patients with chronic bronchitis (n = 113) or asthma (n = 75) and mild to moderate airflow obstruction (forced expiratory volume in one second (FEVy) above 50% but below 2 SD of predicted value) in a crossover study on two days a week apart. Both the patients with asthma and the patients with chronic bronchitis varied considerably in their responses to the salbutamol and the ipratropium bromide. The mean increase in FEV, in the subjects with asthma was higher after salbutamol (0-37 1 or 18% of the prebronchodilator value) than after ipratropium bromide (0-261 or 13%). In chronic bronchitis there was no difference between the increase in FEVy after salbutamol (0-16 1 or 7%) and after ipratropium bromide (0-191 or 8%). When patients were categorised into those with a better response to salbutamol 400 pg and those with a better response to ipratropium bromide 80 pg, patients with chronic bronchitis responded better in general to ipratropium bromide whereas asthmatic patients responded better to salbutamol. The response pattern was also related to allergy and age, allergic patients and patients under 60 being more likely to respond better to salbutamol 400 pg than nonallergic patients and older patients, who benefited more from ipratropium bromide 80 pg. The response pattern was not related to sex, smoking habits, lung function, bronchial reactivity, respiratory symptoms, or number of exacerbations during the preceding year.
Although the bronchodilating effects of inhaled beta2 adrenergic and anticholinergic drugs have been widely studied in patients with asthma and chronic bronchitis, few studies have compared the FEV, response to the two drugs in the same patients. ' 13 The three studies that have done so looked at a small number of patients referred for specialist treatment so it is difficult to known how generally applicable the findings are. The small numbers also make it difficult to relate the bronchodilator responses to the clinical characteristics of the patients. The current study assessed the bronchodilator response to salbutamol 400 pg and ipratropium bromide 80 pg in 188 patients with mild to moderate airflow obstruction selected from general practice. The aim of the study was to investigate the FEV, response to these doses of salbutamol and ipratropium bromide in patients with asthma or chronic bronchitis and to relate the response to the clinical characteristics of the patients.
Methods
The current study was part of an intervention study, designed to assess the long term effects of bronchodilator treatment in patients with asthma and chronic bronchitis. 4 One hundred and eighty eight patients of 30 years and over with mild to moderate airflow obstruction were recruited from 29 general practices. FEV1 had to be two standard deviations below their FEV1% predicted value5 but above 50%.
All subjects had participated in the intervention study for 12 months before the current study was carried out.
PATIENTS
One hundred and thirteen patients with chronic bronchitis and 75 patients with asthma were included in the study ( to report the medication used each week. During the study year the symptomatically treated patients used the same number of dry powder inhalations of salbutamol as of ipratropium-a mean of 0-6 (SD 0-8) a day. The medication the patients had used in the preceding year was known, and used to determine whether there was evidence of tolerance to ipratropium bromide or salbutamol. MEASUREMENTS FEV, forced vital capacity (FVC), and inspiratory vital capacity (IVC) were assessed before and 15 minutes after inhalation of 400 ,g salbutamol and before and 45 minutes after 80 pg ipratropium bromide, both given by metered dose inhaler. Data were derived from the curve with the largest sum of FVC and FEV, (out of three measurements). All bronchodilator medication was discontinued eight hours before the start of the test. FEV1 and FVC were measured by three doctors and two laboratory workers trained in using the Microspiro spirometer HI-298 (Chest Corporation, Tokyo). This spirometer measures instantaneous flow, which is electronically integrated to give volume.8 IVC was measured with a wet spirometer (Gould, Bilthoven, The Netherlands).
Bronchial reactivity (PC20) was tested by means ofa histamine challenge test as described by Cockcroft et al.9 Symptoms were assessed by the MRC-ECCS questionnaire (Dutch version)'0 and quantified by addition to provide a score of 0-8. 4 Smoking history was assessed in pack years (number of packets of cigarettes smoked daily x years of smoking). Allergy was tested with seven radioallergosorbent tests (RAST) (pollen: wild flowers, grasses, trees; animals: cats and dogs; house dust mite; Aspergillus fumigatus) (Pharmacia AB, Uppsala, Sweden). Patients were considered to be allergic if at least one RAST response was positive. The allergy response was measured semiquantitatively on a scale ranging from 0 (no response) to 4 (strong response). The scores for all seven tests were added to provide an allergy score.II ANALYSES Change in FEV1 in response to 400 pg salbutamol and 80 pg ipratropium bromide was related to the clinical characteristics of the patients by means ofpattern recognition.3 With this method the total bronchodilator response after both drugs is 100% and the response is classified as follows. Response class 1 More than 75% of the total response after salbutamol, whatever the order of drug administration. Response class 2 More than 75% of the total response when salbutamol was given first, 25-75% when it was given second. Response class 3 From 25% to 75% of the total response caused by either salbutamol or ipratropium bromide, whatever the order; or more than 75% of total response caused by either salbutamol or ipratropium bromide, whichever was given first. Response class 4 More than 75% of total response when ipratropium bromide was given first, 25-75% when it was given second. Response class 5 More than 75% of total response caused by ipratropium bromide, whatever the order.
Response patterns were correlated with pulmonary disease (chronic bronchitis or asthma), age, sex, allergy, number of exacerbations, smoking or non-smoking, pack years, symptoms, mean baseline of FEV1, and geometric mean PC20 during the 12 The possibility of tolerance to ipratropium bromide or salbutamol after the 12 month intervention study was investigated in two ways. Firstly, the increases in FEV1 to salbutamol and to ipratropium bromide (given as first drug) in patients who had used these drugs continuously were compared; then the responses in patients who had used one of the drugs symptomatically were compared with the responses in patients who had used the same drug continuously. These differences were tested by means of the non-paired Student's t test. Secondly, a MANOVA procedure was carried out, in which the drug used in the preceding year was the independent variable and the increase in FEV, to salbutamol or to ipratropium bromide the dependent variable. Asthma versus chronic bronchitis and continuous versus symptomatic treatment were defined as two binary grouping factors.
The initial FEV, (on the first day of the current crossover study) was incorporated as a covariate in this multivariate model. (fig 2a-c) . The regression coefficient for the effect of ipratropium bromide in asthmatic patients did not deviate significantly from zero. In general (fig 2c) , patients under the age of 60 appeared to show a greater increase in FEV, with sal-FEV, (1) butamol, whereas patiei benefited more from i (p < 0 005).
TOLERANCE TO SALBUTAM BROMIDE
There was no difference i in response to salbutamol or ipratropium tic patients bromide between patients who had used one of these drugs in the preceding year and those who had not ( 
